Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Asset Writedowns and Impairment (2019 - 2024)

Heron Therapeutics (HRTX) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $828000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Asset Writedowns and Impairment rose 437.66% year-over-year to $828000.0, compared with a TTM value of $4.4 million through Sep 2024, up 716.05%, and an annual FY2023 reading of $617000.0, up 195.22% over the prior year.
  • Asset Writedowns and Impairment was $828000.0 for Q3 2024 at Heron Therapeutics, down from $3.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $3.3 million in Q2 2024 and bottomed at $8000.0 in Q3 2020.
  • Average Asset Writedowns and Impairment over 5 years is $337894.7, with a median of $124000.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment soared 2811.11% in 2020, then tumbled 84.22% in 2021.
  • Year by year, Asset Writedowns and Impairment stood at $786000.0 in 2020, then crashed by 84.22% to $124000.0 in 2021, then crashed by 36.29% to $79000.0 in 2022, then skyrocketed by 94.94% to $154000.0 in 2023, then surged by 437.66% to $828000.0 in 2024.
  • Business Quant data shows Asset Writedowns and Impairment for HRTX at $828000.0 in Q3 2024, $3.3 million in Q2 2024, and $170000.0 in Q1 2024.